Temelimab versus placebo in patients with post-COVID condition

Simple item page
dc.contributor.authorNehme, Mayssam
dc.contributor.authorHund Georgiadis, Margret
dc.contributor.authorCorral Beamonte, Esther Del
dc.contributor.authorBridevaux, Pierre Olivier
dc.contributor.authorHoepner, Robert
dc.contributor.authorPenner, Iris Katharina
dc.contributor.authorStrobel, Joana
dc.contributor.authorFretz, Gregory
dc.contributor.authorBoada Rovira, Mercè
dc.contributor.authorGuisado Vasco, Pablo
dc.contributor.authoret al.
dc.date.accessioned2026-07-22T14:18:14Z
dc.date.available2026-07-22T14:18:14Z
dc.date.issued2026
dc.description.abstractMore than 400 million individuals are estimated to have been affected by post-COVID condition or long COVID. This condition can lead to significantly decreased quality of life and increased individual and societal costs. Temelimab, a monoclonal IgG4 backbone antibody targeting HERV-W ENV, may be a potential treatment for post-COVID. In adults with persistent symptoms due to post-COVID condition, the use of Temelimab did not show improvement in fatigue compared to placebo.en
dc.description.filiationUEMspa
dc.description.impact7.5 Q1 JCR 2025
dc.description.impact2.689 Q1 SJR 2025
dc.description.impactNo data IDR 2024
dc.description.sponsorshipEste estudio está financiado parcialmente por la Oficina Federal de Salud Pública de Suiza, en el marco del Programa Federal de Financiación para Medicamentos contra la COVID-19. GeNeuro SA es el promotor del ensayo clínico (3 Chemin du Pré-Fleuri, CH-1228 Plan-les-Ouates, Suiza).es
dc.identifier.citationNehme, M., Hund-Georgiadis, M., Corral Beamonte, E. D., Bridevaux, P.-O., Hoepner, R., Penner, I.-K., Strobel, J., Fretz, G., Rovira, M. B., Puchades, F., Landi, F., Vasco, P. G., Guaraldi, G., Cordero, F. M., Sebastianelli, L., Sarmati, L., Berthuy, N., Wojcik, J., Keddad, K., … Guessous, I. (2026). Temelimab versus placebo in patients with post-COVID condition. Brain, Behavior, and Immunity, 138, 106892. https://doi.org/10.1016/j.bbi.2026.106892
dc.identifier.doi10.1016/j.bbi.2026.106892
dc.identifier.issn0889-1591
dc.identifier.issn1090-2139
dc.identifier.urihttps://hdl.handle.net/11268/17301
dc.language.isoeng
dc.peerreviewedSi
dc.relation.publisherversionhttps://doi.org/10.1016/j.bbi.2026.106892
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.otherMedicina, Salud y Deportes
dc.subject.otherSíndrome Post Agudo de COVID-19
dc.subject.otherAnticuerpos Monoclonales
dc.subject.otherInmunoterapia
dc.subject.sdgGoal 3: Ensure healthy lives and promote well-being for all at all ages
dc.subject.sdgGoal 9: Build resilient infrastructure, promote sustainable industrialization and foster innovation
dc.subject.sdgGoal 17: Partnerships
dc.subject.unescoCiencias médicas
dc.subject.unescoInmunología
dc.subject.unescoFarmacología
dc.titleTemelimab versus placebo in patients with post-COVID conditionen
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationf2cb48d1-2d0e-4855-b6c9-fda9346183ee
relation.isAuthorOfPublication.latestForDiscoveryf2cb48d1-2d0e-4855-b6c9-fda9346183ee

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Temelimab_versus_placebo.pdf
Size:
1.92 MB
Format:
Adobe Portable Document Format
Download

Collections

Área de Ciencias de la Salud